CIK 0000949858
- Non-accelerated filer
- Smaller reporting company
ACHIEVE LIFE SCIENCES, INC.
Sign in to watch- Tickers
- ACHV QUIT
- Exchange
- Nasdaq
- Industry
- In Vitro & In Vivo Diagnostic Substances
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 954343413
- Phone
- +1 425-686-1500
- Business address
- 22722 29TH DR. SE, SUITE 100, SEATTLE, WA, 98021
- Former names
- ONCOGENEX PHARMACEUTICALS, INC., SONUS PHARMACEUTICALS INC
Securities
- ACHV Common stock Nasdaq
- QUIT Common Shares Nasdaq
- 4 Open-market buy CFO and Secretary bought 3,000 shares at an average $2.43 ($7,278)
- 4/A Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Open-market buy President and CEO bought 5,000 shares at an average $3.99 ($19,945)
- 3 Insider Initial Statement of Ownership
- 3 Insider Initial Statement of Ownership
- 4 Open-market buy CFO and Secretary bought 10,000 shares at an average $6.77 ($67,700)
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
- 4 Grant or award President & CEO acquired 2,321 shares (grant or award)
- 3 Insider Initial Statement of Ownership
- 3 Insider Initial Statement of Ownership
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
Page 20 of 24 · 465 filings